

# INNOVATION IS GREAT

BRITAIN & NORTHERN IRELAND



## The 4th Healthcare and MedTech Mission to Taiwan

*The UK Science & Innovation Network (SIN) Taipei, and Department of International Trade (DIT) are organising the 4<sup>th</sup> Technology outward mission to Taiwan to assist UK SMEs, spinouts and start-ups to export, find co-development partners and Medical investors in January 2019.*

The mission provides selected participants sponsorship and tailor-made programmes of visits, workshops and 1-on-1 meetings, targeted at innovative UK SMEs and research organisations involved in diagnostic technology. The mission is now in its fourth year, UK companies and universities are able to explore areas of joint interest, research, and meet commercial partners, including potential clients and investors in Taiwan. We help to build your network and presence as well as introduce you to the right organisations to accelerate your financial and business growth.

We see particular opportunities for participants with expertise in these areas:

- Digital Health - AIoT healthcare solution, smart hospital, medical imaging
- Precision Medicine - genome analysis, companion diagnostics, precision surgery
- Regenerative Medicine - cell & gene therapy manufacturing, tissue engineering & biomaterials

Application form for the 2019 Medical Technology Mission to Taiwan, to be held on 21-23 January 2019. The closing date for applications and registrations are Friday 14 December 2018.

<https://goo.gl/forms/Msd9dMadMnjctNtz1>

### About the Taiwan Market

Taiwan—the world's 22<sup>nd</sup> largest economy, situated in the middle of the Asia-Pacific region—is an excellent route for foreign companies into the emerging health care economies of Asia, while also being an ideal platform, from which to enter the Chinese market. Taiwan's welcoming culture and reliable business environment underpin the potential for strong partnerships.

Joint R&D opportunities lie in Taiwan's ICT strengths, as Taiwan excels in hardware development with a well-established and professional supply chain. Taiwan's leading ICT giants are actively seeking investment opportunities and R&D projects as they diversify into the healthcare industry. They welcome horizontal and vertical integration models for medical devices and healthcare services through M&A or forming strategic partnerships.

In the biotechnology sector, capitalization of local publicly-listed biotech companies is valued at £18.6 billion with a total revenue of £5.5 billion up 17% since 2015. With over 105 bio-related IPO companies, Taiwan is a prime location for industry investment, partnerships, and licensing opportunities, as a result pharmaceutical companies like GSK and AstraZeneca are actively running clinical R&D centres in Taiwan.

Taiwan is a significant global market, with National Health Expenditure accounting for 6.3% of GDP (£27 billion) this is expected to grow annually at a rate of 4.8%. It applies WHO/FDA healthcare standards and has a high level of IP protection. Taiwan's high quality universal health coverage single payer National Health Insurance (NHI) program covers 99.9% of the island's 23 million population with public satisfaction at 83.1%. Looking ahead Taiwan has a number of serious health challenges that need to be addressed, not least of all an aging population, international cooperation will be vital to solving these issues.

### Dates:

**21<sup>st</sup> - 23<sup>rd</sup> January 2019**

### Apply before:

**14<sup>th</sup> December 2018**

### Organised by:



British Office

**In partnership with:**

